Alkaptonuria is a rare genetic disorder caused by pathogenic variants in the HGD gene, leading to a deficiency of the enzyme homogentisate 1,2-dioxygenase. As a consequence, homogentisic acid accumulates, responsible for the darkening of urine, ochronosis, and a progressive adult-onset arthropathy.
Alkaptonuria
Alkaptonuria is a congenital error of tyrosine and phenylalanine metabolism. It is caused by biallelic variants in HGD, a gene that encodes homogentisate 1,2-dioxygenase. This enzyme participates in the conversion of homogentisic acid to 4-maleilacetoacetate; when its activity is reduced or absent, homogentisic acid accumulates, oxidizes, and polymerizes to form ochro
Symptoms
The first manifestations can be observed in childhood by the darkening of the urine when in contact with air, although many people do not develop evident symptoms until adulthood, generally after 30 years of age. The classic triad includes dark urine, visible ochronosis in the auricular cartilage and sclera, and progressive ochronotic arthropathy, especially in the spine, hips, knees, and shoulders. Over time, chronic pain, limited mobility, valvular calcification or cardiovascular disease may appear, as well as renal or prostatic lithiasis and other genitourinary complications.
Disease management
There is no preventive strategy that avoids the disease in affected individuals, so management is aimed at reducing homogentisic acid accumulation, preventing complications, and treating symptoms. Clinical follow-up, pain control, adapted exercise, physical therapy, and monitoring of joints, spine, heart valves, kidneys, and prostate are recommended. Low-protein diets or those with tyrosine and phenylalanine restriction have limited utility and should be supervised. Nitisinone can markedly decrease homogentisic acid production, but requires monitoring due to increased tyrosine and other potential adverse effects.
Genes analyzed
Bibliography
Goicoechea De Jorge E, Lorda I, Gallardo ME, et al. Alkaptonuria in the Dominican Republic: identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene. J Med Genet. 2002 Jul;39(7):E40.
Introne WJ, Perry M, Chen M. Alkaptonuria. 2003 May 9 [updated 2021 Jun 10]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Müller CR, Fregin A, Srsen S, et al. Allelic heterogeneity of alkaptonuria in Central Europe. Eur J Hum Genet. 1999 Sep;7(6):645-51.
Sharabi AF, Goudar RB. Alkaptonuria. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
